Physician profile
David B Stanton
NPI 1821101163
$1,251.63
in general payments reported to CMS, 2019-2025
17 companies · $440 in 2025
The $440 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.42 · 2020: $15.90 · 2022: $17.88 · 2023: $237 · 2024: $505 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150 · Education: $31.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.10 |
| Education | $31.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $252.78 | 2019-2025 | |
| Janssen Biotech, INC. | $149.87 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Madrigal Pharmaceuticals | $115.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $100.46 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.38 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $88.92 | 2023-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $88.30 | 2024 | Voquezna |
| Ardelyx, INC. | $88.26 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $51.35 | 2025 | Dupixent |
| Celltrion USA INC. | $48.62 | 2024 | Zymfentra |
| Abbvie INC. | $31.10 | 2022-2023 | Viberzi, Linzess |
| Qol Medical, LLC | $30.98 | 2023 | Sucraid |
| Daiichi Sankyo INC. | $27.81 | 2024 | Injectafer |
| Shionogi INC | $23.67 | 2019 | |
| Lilly USA, LLC | $21.69 | 2024 | Omvoh |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $21.30 | 2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $14.55 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.